Supplementary Tables – Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study

Supplemental Table 1: Code lists for safety event algorithms

Supplemental Table 2. Incidence of safety events by case definition in the overall cohort (n=44,045)

Supplemental Table 3: Incidence of safety events by case definition before and after the start of ICIs in the advanced-stage NSCLC cohort

Supplemental Table 4: Incidence of selected safety events in the first 6 months and after 6 months of ICIs in the advanced-stage NSCLC cohort (N=5,278)